Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.
Identifieur interne : 000915 ( PubMed/Corpus ); précédent : 000914; suivant : 000916Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.
Auteurs : Alimuddin Zumla ; Martin Rao ; Robert S. Wallis ; Stefan H E. Kaufmann ; Roxana Rustomjee ; Peter Mwaba ; Cris Vilaplana ; Dorothy Yeboah-Manu ; Jeremiah Chakaya ; Giuseppe Ippolito ; Esam Azhar ; Michael Hoelscher ; Markus MaeurerSource :
- The Lancet. Infectious diseases [ 1474-4457 ] ; 2016.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Cytokines, Vitamins.
- immunology : Communicable Diseases, Host-Pathogen Interactions.
- methods : Cell- and Tissue-Based Therapy.
- therapy : Communicable Diseases.
- Drug Resistance, Humans.
Abstract
Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.
DOI: 10.1016/S1473-3099(16)00078-5
PubMed: 27036359
Links to Exploration step
pubmed:27036359Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.</title><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:affiliation>Centre for Clinical Microbiology, Division of Infection and Immunity, University College London (UCL), London, UK; National Institute for Health Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Wallis, Robert S" sort="Wallis, Robert S" uniqKey="Wallis R" first="Robert S" last="Wallis">Robert S. Wallis</name><affiliation><nlm:affiliation>Aurum Institute, Johannesburg, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Kaufmann, Stefan H E" sort="Kaufmann, Stefan H E" uniqKey="Kaufmann S" first="Stefan H E" last="Kaufmann">Stefan H E. Kaufmann</name><affiliation><nlm:affiliation>Max Planck Institute for Infection Biology, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rustomjee, Roxana" sort="Rustomjee, Roxana" uniqKey="Rustomjee R" first="Roxana" last="Rustomjee">Roxana Rustomjee</name><affiliation><nlm:affiliation>South African Medical Research Council, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Mwaba, Peter" sort="Mwaba, Peter" uniqKey="Mwaba P" first="Peter" last="Mwaba">Peter Mwaba</name><affiliation><nlm:affiliation>University of Zambia-UCL Medical School (UNZA-UCLMS) Research and Training Project, University Teaching Hospital, Lusaka, Zambia; Ministry of Health, Lusaka, Zambia.</nlm:affiliation></affiliation></author><author><name sortKey="Vilaplana, Cris" sort="Vilaplana, Cris" uniqKey="Vilaplana C" first="Cris" last="Vilaplana">Cris Vilaplana</name><affiliation><nlm:affiliation>Unitat de Tuberculosi Experimental Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol CIBER Enfermedades Respiratorias, Can Ruti Campus, Edifici Laboratoris de Recerca, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Yeboah Manu, Dorothy" sort="Yeboah Manu, Dorothy" uniqKey="Yeboah Manu D" first="Dorothy" last="Yeboah-Manu">Dorothy Yeboah-Manu</name><affiliation><nlm:affiliation>Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Chakaya, Jeremiah" sort="Chakaya, Jeremiah" uniqKey="Chakaya J" first="Jeremiah" last="Chakaya">Jeremiah Chakaya</name><affiliation><nlm:affiliation>Kenya Medical Research Institute, Nairobi, Kenya.</nlm:affiliation></affiliation></author><author><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Azhar, Esam" sort="Azhar, Esam" uniqKey="Azhar E" first="Esam" last="Azhar">Esam Azhar</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Hoelscher, Michael" sort="Hoelscher, Michael" uniqKey="Hoelscher M" first="Michael" last="Hoelscher">Michael Hoelscher</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany; DZIF German Centre for Infection Research, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: markus.maeurer@ki.se.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27036359</idno><idno type="pmid">27036359</idno><idno type="doi">10.1016/S1473-3099(16)00078-5</idno><idno type="wicri:Area/PubMed/Corpus">000915</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000915</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.</title><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:affiliation>Centre for Clinical Microbiology, Division of Infection and Immunity, University College London (UCL), London, UK; National Institute for Health Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Wallis, Robert S" sort="Wallis, Robert S" uniqKey="Wallis R" first="Robert S" last="Wallis">Robert S. Wallis</name><affiliation><nlm:affiliation>Aurum Institute, Johannesburg, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Kaufmann, Stefan H E" sort="Kaufmann, Stefan H E" uniqKey="Kaufmann S" first="Stefan H E" last="Kaufmann">Stefan H E. Kaufmann</name><affiliation><nlm:affiliation>Max Planck Institute for Infection Biology, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rustomjee, Roxana" sort="Rustomjee, Roxana" uniqKey="Rustomjee R" first="Roxana" last="Rustomjee">Roxana Rustomjee</name><affiliation><nlm:affiliation>South African Medical Research Council, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Mwaba, Peter" sort="Mwaba, Peter" uniqKey="Mwaba P" first="Peter" last="Mwaba">Peter Mwaba</name><affiliation><nlm:affiliation>University of Zambia-UCL Medical School (UNZA-UCLMS) Research and Training Project, University Teaching Hospital, Lusaka, Zambia; Ministry of Health, Lusaka, Zambia.</nlm:affiliation></affiliation></author><author><name sortKey="Vilaplana, Cris" sort="Vilaplana, Cris" uniqKey="Vilaplana C" first="Cris" last="Vilaplana">Cris Vilaplana</name><affiliation><nlm:affiliation>Unitat de Tuberculosi Experimental Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol CIBER Enfermedades Respiratorias, Can Ruti Campus, Edifici Laboratoris de Recerca, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Yeboah Manu, Dorothy" sort="Yeboah Manu, Dorothy" uniqKey="Yeboah Manu D" first="Dorothy" last="Yeboah-Manu">Dorothy Yeboah-Manu</name><affiliation><nlm:affiliation>Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Chakaya, Jeremiah" sort="Chakaya, Jeremiah" uniqKey="Chakaya J" first="Jeremiah" last="Chakaya">Jeremiah Chakaya</name><affiliation><nlm:affiliation>Kenya Medical Research Institute, Nairobi, Kenya.</nlm:affiliation></affiliation></author><author><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Azhar, Esam" sort="Azhar, Esam" uniqKey="Azhar E" first="Esam" last="Azhar">Esam Azhar</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Hoelscher, Michael" sort="Hoelscher, Michael" uniqKey="Hoelscher M" first="Michael" last="Hoelscher">Michael Hoelscher</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany; DZIF German Centre for Infection Research, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: markus.maeurer@ki.se.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Lancet. Infectious diseases</title><idno type="eISSN">1474-4457</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Cell- and Tissue-Based Therapy (methods)</term><term>Communicable Diseases (immunology)</term><term>Communicable Diseases (therapy)</term><term>Cytokines (therapeutic use)</term><term>Drug Resistance</term><term>Host-Pathogen Interactions (immunology)</term><term>Humans</term><term>Vitamins (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Cytokines</term><term>Vitamins</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Communicable Diseases</term><term>Host-Pathogen Interactions</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell- and Tissue-Based Therapy</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Communicable Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27036359</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>02</Day></DateCreated><DateCompleted><Year>2016</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.</ArticleTitle><Pagination><MedlinePgn>e47-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(16)00078-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(16)00078-5</ELocationID><Abstract><AbstractText>Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Clinical Microbiology, Division of Infection and Immunity, University College London (UCL), London, UK; National Institute for Health Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallis</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Aurum Institute, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufmann</LastName><ForeName>Stefan H E</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Infection Biology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rustomjee</LastName><ForeName>Roxana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mwaba</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Zambia-UCL Medical School (UNZA-UCLMS) Research and Training Project, University Teaching Hospital, Lusaka, Zambia; Ministry of Health, Lusaka, Zambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilaplana</LastName><ForeName>Cris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unitat de Tuberculosi Experimental Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol CIBER Enfermedades Respiratorias, Can Ruti Campus, Edifici Laboratoris de Recerca, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeboah-Manu</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakaya</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ippolito</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azhar</LastName><ForeName>Esam</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoelscher</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany; DZIF German Centre for Infection Research, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeurer</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: markus.maeurer@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Host-Directed Therapies Network consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MRC_G1001337</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014815">Vitamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="Y">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Marais</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talom</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tientcheu</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ntoumi</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koussounda</LastName><ForeName>F K</ForeName><Initials>FK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wejse</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Eskild</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter Lawætz</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruhwald</LastName><ForeName>Morten</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aseffa</LastName><ForeName>Abraham</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Maryline</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adegnika</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tientcheu</LastName><ForeName>Leopold</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonio</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoelscher</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velavan</LastName><ForeName>Thirumalaisamy P</ForeName><Initials>TP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauffman</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeboah-Manu</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gyapong</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ippolito</LastName><ForeName>Guiseppi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chakaya</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rasolof</LastName><ForeName>Voahangy</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rakotosamimanana</LastName><ForeName>Niaina</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maiga</LastName><ForeName>Almoustapha</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diarra</LastName><ForeName>Bassirou</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macete</LastName><ForeName>Eusebio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Basterio</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bero</LastName><ForeName>Celso</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grobusch</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van de Werf</LastName><ForeName>Tjip</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oukem</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dyrhol-Riise</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bjune</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fylkesnes</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieye</LastName><ForeName>Tandakha</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieye</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieye</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mbengue</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diop</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiam</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camara</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mbow</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toure</LastName><ForeName>M O</ForeName><Initials>MO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russel</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rustomjee</LastName><ForeName>Roxana</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Nalini</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padayachin</LastName><ForeName>Nesri</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyirenda</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallis</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Churchyard</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madansein</LastName><ForeName>Rajhmun</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steyn</LastName><ForeName>Andrie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramjee</LastName><ForeName>Gita</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiepiela</LastName><ForeName>Photini</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanne</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinson</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayosi</LastName><ForeName>Bongani</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volmink</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nachega</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loots</LastName><ForeName>Glaudina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilaplana</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardona</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Basteiro</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Placencia</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menendez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aklilu</LastName><ForeName>Eleni</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maeurer</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parida</LastName><ForeName>Shreemanta</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reither</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gagneux</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kibaki</LastName><ForeName>Gibson</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mfinanga</LastName><ForeName>Sayoki</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mboko</LastName><ForeName>Leonard</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mfinanga</LastName><ForeName>Elirehema</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdulla</LastName><ForeName>Salim</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaula</LastName><ForeName>Zainab</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munderi</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaleebu</LastName><ForeName>Pontiano</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McHugh</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gant</LastName><ForeName>Vanya</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fortune</LastName><ForeName>Farida</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corrah</LastName><ForeName>Tumena</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaffar</LastName><ForeName>Shabbar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elkington</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schito</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hafner</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mwaba</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapata</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulenga</LastName><ForeName>Modest</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chanda</LastName><ForeName>Duncan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chizema</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luo</LastName><ForeName>Nkandu</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27036359</ArticleId><ArticleId IdType="pii">S1473-3099(16)00078-5</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(16)00078-5</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000915 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000915 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27036359
|texte= Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27036359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |